Phase I study of personalized peptide vaccination with transdermal adjuvant for cancer patients
Not Applicable
- Conditions
- malignant tumor
- Registration Number
- JPRN-UMIN000030854
- Lead Sponsor
- Kurume University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Patient meets the followings: 1) under or have a plan of treatment with molecular tagetting or chemotherapy during this study 2) other severe diseases 3) severe allagic dideases 4) sensitive to adhesive plaster 5) woman with plegnancy or under milk feeding, man who is not accept contaception 6) doctor consider who is not appropriate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of adeverse events using CTCAE v.4.0
- Secondary Outcome Measures
Name Time Method Peptide-specigic IgG and CTL response after 6th vaccination